Q-omics provides the consensus-scored COQ10A profile across patient tissues and cancer cell-line models. COQ10A expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, COQ10A is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, COQ10A RNA expression shows 18,162 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight PAAD, KIRC, and UVM as cancer lineages where COQ10A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for COQ10A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes COQ10A survival associations across molecular data types. COQ10A RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible COQ10A RNA expression–survival associations across cancer types. High COQ10A expression shows unfavorable associations in KIRC, COAD and SKCM, but favorable associations in PAAD, KIRP and LAML. The PAAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for COQ10A RNA expression.
This table summarizes COQ10A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for COQ10A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. COQ10A shows lower tumor expression in KIRC, THCA, KIRP, BRCA and LUSC and higher tumor expression in LIHC. The KIRC box plot shows higher COQ10A RNA expression in normal versus tumor tissue (log2 FC = −0.852, t-test p < 0.001).
This table shows molecular features associated with COQ10A in patient tissues and cancer cell lines. In patient samples, COQ10A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, COQ10A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
